VG-3927 Clinical Trials

Size	Price	Qty
1mg	USD 197
5mg	USD 347

Clinical Trials

A clinical trial conducted by industry sponsor Vigil Neuroscience, Inc. evaluated the investigational compound VG-3927 in human subjects. This first-in-human, randomized, placebo-controlled Phase 1 study assessed single and multiple ascending doses in healthy adult participants and cohorts with Alzheimer's disease to evaluate safety, tolerability, and pharmacokinetic profiles. Having reached completed recruitment status, the study established key preliminary data to support the clinical development landscape of this therapeutic candidate.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06343636	COMPLETED	Healthy; Alzheimer Disease	Vigil Neuroscience, Inc.	2023-09-22	PHASE1

(data from https://clinicaltrials.gov, updated on 2025-02-07)

Check the VG-3927 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

VG-3927 selectively binds to and activates triggering receptor expressed on myeloid cells 2 (TREM2), stimulating downstream intracellular signaling pathways within central nervous system microglia. This agonistic activity induces an anti-inflammatory microglial functional state and enhances neuroprotective cellular survival and clearance capabilities, directly targeting the neuroinflammatory pathology underlying Alzheimer's disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).